3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
72
Breast Neoplasms
9
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Prostate Cancer Metastatic
3
Metastatic Castration Resistant Prostate Cancer
3
Bulbo-Spinal Atrophy, X-Linked
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Metastatic Hormone Sensitive Prostate Cancer
2
Melanoma
2
mCRPC
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Seizures
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Pancreatic Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
Paclitaxel
96
Carboplatin
81
Bevacizumab
62
Gemcitabine
36
liposomal doxorubicin
32
pembrolizumab
30
Topotecan
26
olaparib
23
Taxes
23
niraparib
17
Immunoglobulin G
17
Disulfides
17
Docetaxel
16
Cyclophosphamide
16
Cisplatin
14
Nivolumab
11
rucaparib
10
durvalumab
10
Doxorubicin
9
Albumin-Bound Paclitaxel
8
sargramostim
7
pazopanib
7
fludarabine phosphate
7
fludarabine
7
avelumab
7
Magnetic Resonance Spectroscopy
7
Ifosfamide
7
epacadostat
6
Trabectedin
6
Sorafenib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Ovarian Neoplasms
×
enzalutamide
×
Clear all
No trials found.